glp-1 tricare Q&A: For Life Coverage of Weight Loss Medications > Naval Health Clinic Charleston > Articles 1 long term Tricare Dropped My Zepbound! What

NICE recommends reviewing GLP-1 receptor agonist therapy at six months to assess efficacy and tolerability

Ongoing research highlights the significant clinical potential of incretin-based therapies, especially in emerging areas such as central nervous system disorders, substance use, and post-transplant care

They can also help preserve muscle and improve insulin sensitivity

MEDI0382, a GLP1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a singledose, healthysubject, randomized, phase 1 study

(34) However, the focus of this review was primarily on the cardiovascular and renal benefits of these therapies, with little to no emphasis on musculoskeletal outcomes

Men were slightly more likely than women to experience this effect (77% compared to 72%, respectively)